Nektar links ‘softening’ response to bempegaldesleukin to CMC issues

A year after Nektar reported decreasing responses to its bempegaldesleukin/Opdivo combination, the biotech thinks it has zeroed in on the reason -- manufacturing. However, the pattern isn’t consistent across different tumor types.

Shares of Nektar Therapeutics (NASDAQ:NKTR) fell $7.77 (26%) to $29.57 in after-hours trading. ...